Precigen (NASDAQ:PGEN) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate. This is a 30 percent decrease over losses of $(0.10) per share from the same period last year.
Nuvectis Pharma, Inc. Announces A Collaboration With Mayo Clinic To Evaluate NXP800 In An Investigator-Sponsored Clinical Trial In Cholangiocarcinoma
Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by investigators from Mayo
